Cargando…

JAK-STAT pathway inhibitors in dermatology()

The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions. The main derma...

Descripción completa

Detalles Bibliográficos
Autores principales: Miot, Hélio Amante, Criado, Paulo Ricardo, de Castro, Caio César Silva, Ianhez, Mayra, Talhari, Carolina, Ramos, Paulo Müller
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404561/
https://www.ncbi.nlm.nih.gov/pubmed/37230920
http://dx.doi.org/10.1016/j.abd.2023.03.001
_version_ 1785085325710721024
author Miot, Hélio Amante
Criado, Paulo Ricardo
de Castro, Caio César Silva
Ianhez, Mayra
Talhari, Carolina
Ramos, Paulo Müller
author_facet Miot, Hélio Amante
Criado, Paulo Ricardo
de Castro, Caio César Silva
Ianhez, Mayra
Talhari, Carolina
Ramos, Paulo Müller
author_sort Miot, Hélio Amante
collection PubMed
description The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions. The main dermatological targets of JAK-STAT pathway inhibitors are inflammatory or autoimmune diseases such as psoriasis, vitiligo, atopic dermatitis and alopecia areata; however, several dermatoses are under investigation to expand this list of indications. As JAK-STAT pathway inhibitors should gradually occupy a relevant space in dermatological prescriptions, this review presents the main available drugs, their immunological effects, and their pharmacological characteristics, related to clinical efficacy and safety, aiming to validate the best dermatological practice.
format Online
Article
Text
id pubmed-10404561
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Sociedade Brasileira de Dermatologia
record_format MEDLINE/PubMed
spelling pubmed-104045612023-08-08 JAK-STAT pathway inhibitors in dermatology() Miot, Hélio Amante Criado, Paulo Ricardo de Castro, Caio César Silva Ianhez, Mayra Talhari, Carolina Ramos, Paulo Müller An Bras Dermatol Review The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions. The main dermatological targets of JAK-STAT pathway inhibitors are inflammatory or autoimmune diseases such as psoriasis, vitiligo, atopic dermatitis and alopecia areata; however, several dermatoses are under investigation to expand this list of indications. As JAK-STAT pathway inhibitors should gradually occupy a relevant space in dermatological prescriptions, this review presents the main available drugs, their immunological effects, and their pharmacological characteristics, related to clinical efficacy and safety, aiming to validate the best dermatological practice. Sociedade Brasileira de Dermatologia 2023 2023-05-23 /pmc/articles/PMC10404561/ /pubmed/37230920 http://dx.doi.org/10.1016/j.abd.2023.03.001 Text en © 2023 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Miot, Hélio Amante
Criado, Paulo Ricardo
de Castro, Caio César Silva
Ianhez, Mayra
Talhari, Carolina
Ramos, Paulo Müller
JAK-STAT pathway inhibitors in dermatology()
title JAK-STAT pathway inhibitors in dermatology()
title_full JAK-STAT pathway inhibitors in dermatology()
title_fullStr JAK-STAT pathway inhibitors in dermatology()
title_full_unstemmed JAK-STAT pathway inhibitors in dermatology()
title_short JAK-STAT pathway inhibitors in dermatology()
title_sort jak-stat pathway inhibitors in dermatology()
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404561/
https://www.ncbi.nlm.nih.gov/pubmed/37230920
http://dx.doi.org/10.1016/j.abd.2023.03.001
work_keys_str_mv AT miothelioamante jakstatpathwayinhibitorsindermatology
AT criadopauloricardo jakstatpathwayinhibitorsindermatology
AT decastrocaiocesarsilva jakstatpathwayinhibitorsindermatology
AT ianhezmayra jakstatpathwayinhibitorsindermatology
AT talharicarolina jakstatpathwayinhibitorsindermatology
AT ramospaulomuller jakstatpathwayinhibitorsindermatology